News & Updates

Twice-yearly subcutaneous (SC) lenacapavir demonstrates high efficacy, favourable safety, and consistent pharmacokinetics (PK) as pre-exposure prophylaxis (PrEP) for HIV-negative youth (aged 16–25 years) in an analysis of the phase III PURPOSE 1 (P1) and PURPOSE 2 (P2) trials.

The use of antibiotic therapy for 30 days following robot-assisted radical cystectomy (RARC) results in reduced 90-day urinary tract infections (UTIs), infectious complications, UTI-related readmissions, and costs without an increase in adverse events (AEs), a study has shown.